基因疗法开发商BioMarin宣布完成对Inozyme的收购-动脉网

BioMarin Announces Completion of Acquisition of Inozyme

CISION 等信源发布 2025-07-01 20:45



可切换为仅中文







SAN RAFAEL, Calif.

加利福尼亚州圣拉斐尔

，

July 1, 2025

2025年7月1日

/PRNewswire/ -- BioMarin Pharmaceutical Inc. (Nasdaq:

/PRNewswire/ -- BioMarin制药公司（纳斯达克：

BMRN

) said today that it completed the previously announced agreement to acquire Inozyme Pharma, Inc. (Nasdaq:

）今天表示，已完成先前宣布的收购 Inozyme Pharma, Inc.（纳斯达克：

INZY

) for

) 对于

$4.00

4.00美元

per share in an all-cash transaction worth approximately

每股价格，全现金交易，价值约为

$270 million

2.7亿美元

. The acquisition will strengthen BioMarin's enzyme therapies portfolio, adding a late-stage enzyme replacement therapy, INZ-701. The medicine is currently being developed for the treatment of ectonucleotide pyrophosphatase/phosphodiesterase 1 (ENPP1) Deficiency, a rare, serious and progressive genetic condition that affects blood vessels, soft tissues and bones..

收购将加强BioMarin的酶疗法产品组合，新增一种晚期酶替代疗法INZ-701。该药物目前正被开发用于治疗外核苷酸焦磷酸酶/磷酸二酯酶1（ENPP1）缺乏症，这是一种罕见、严重且进展性的遗传疾病，影响血管、软组织和骨骼。

在

May 16, 2025

2025年5月16日

, BioMarin and Inozyme announced that the companies had signed a definitive merger agreement pursuant to which BioMarin commenced a tender offer on

BioMarin 和 Inozyme 宣布两家公司已签署最终合并协议，根据该协议，BioMarin 开始进行要约收购。

June 2, 2025

2025年6月2日

, to acquire all of the issued and outstanding shares of Inozyme common stock (the 'Shares') at a price of

，以每股价格收购Inozyme所有已发行和流通的普通股（“股份”）

$4.00

4.00美元

per share.

每股。

BioMarin's tender offer expired as scheduled at one minute following

BioMarin的要约收购按计划在以下一分钟到期

11:59 p.m., Eastern Daylight Time

晚上11点59分，东部夏令时间

, on

，打开

June 30, 2025

2025年6月30日

and was not further extended (the 'Expiration Date'). Computershare Trust Company, N.A., the depositary for the tender offer, has advised BioMarin that, as of the Expiration Date, a total of 45,455,118 Shares were validly tendered and not validly withdrawn pursuant to the tender offer, representing approximately 70% of the issued and outstanding Shares.

并且没有进一步延长（“到期日”）。Computershare Trust Company, N.A.，作为要约的存款代理，已告知BioMarin，截至到期日，根据要约，总计有45,455,118股股票被有效投标且未被有效撤回，约占已发行和流通股的70%。

Such Shares have been accepted for payment and will be promptly paid for in accordance with the terms of the tender offer. Following the completion of the tender offer, BioMarin completed the acquisition of Inozyme by consummating the merger of Incline Merger Sub, Inc., a wholly-owned subsidiary of BioMarin, with and into Inozyme pursuant to Section 251(h) of the General Corporation Law of the .

此类股份已被接受付款，并将根据要约收购的条款迅速支付。在完成要约收购后，BioMarin通过其全资子公司Incline Merger Sub, Inc.与Inozyme依据《通用公司法》第251(h)条进行合并，完成了对Inozyme的收购。

State of Delaware

特拉华州

. As a result of the merger, all remaining Shares not tendered in the tender offer (other than Shares held by BioMarin and other than Shares held by Inozyme stockholders who are entitled and have properly demanded appraisal in connection with the merger under

由于合并，所有在要约收购中未被认购的剩余股份（生物马林公司持有的股份以及其他根据合并协议有权并已正确要求评估的Inozyme股东持有的股份除外）

Delaware

特拉华州

law) were converted into the right to receive

法律）被转换为接收的权利

$4.00

4.00美元

per share in cash, the same price that was paid in the tender offer. Following completion of the merger, the Shares have ceased trading on the Nasdaq Global Select Market and will be delisted.

每股现金的价格与要约收购中支付的价格相同。合并完成后，股票已停止在纳斯达克全球精选市场交易，并将被退市。

Goldman Sachs & Co. LLC acted as exclusive financial advisor to BioMarin, and Cooley LLP served as legal counsel. Centerview Partners LLC acted as exclusive financial advisor to Inozyme, and Goodwin Procter LLP and WilmerHale LLP, which has served as corporate counsel to Inozyme since its founding, served as legal counsel..

高盛有限责任公司担任BioMarin的独家财务顾问，科利律师事务所担任法律顾问。Centerview Partners有限责任公司担任Inozyme的独家财务顾问，Goodwin Procter律师事务所和自Inozyme成立以来一直担任其公司法律顾问的WilmerHale律师事务所担任法律顾问。

About

关于

BioMarin

BioMarin is a global biotechnology company dedicated to translating the promise of genetic discovery into medicines that make a profound impact on the life of each patient. The

BioMarin是一家全球生物技术公司，致力于将基因发现的希望转化为对每位患者生活产生深远影响的药物。

San Rafael, California

加利福尼亚州圣拉斐尔

-based company, founded in 1997, has a proven track record of innovation with eight commercial therapies and a strong clinical and preclinical pipeline. Using a distinctive approach to drug discovery and development, BioMarin seeks to unleash the full potential of genetic science by pursuing category-defining medicines that offer new possibilities for people living with genetically defined conditions around the world.

总部位于-的公司，成立于1997年，拥有八种商业疗法和强大的临床及临床前管线，创新成果显著。BioMarin采用独特的药物发现与开发方法，致力于通过研发开创性类别的药物，充分释放基因科学的潜力，为全球患有基因定义疾病的患者提供新的可能。

To learn more, please visit .

要了解更多信息，请访问。

www.biomarin.com

。

About Inozyme

关于Inozyme

Inozyme Pharma is a clinical-stage biopharmaceutical company, with approximately 50 employees based in Boston. The company is dedicated to developing innovative therapeutics that target the PPi-Adenosine Pathway, a key regulator of bone health and blood vessel function. Disruptions in this pathway underlie a range of severe diseases, including ENPP1 Deficiency.

Inozyme Pharma是一家临床阶段的生物制药公司，约有50名员工，总部位于波士顿。该公司致力于开发针对PPi-腺苷通路的创新疗法，这一通路是骨骼健康和血管功能的关键调节因子。该通路的紊乱是包括ENPP1缺乏症在内的一系列严重疾病的基础。

Our lead investigational therapy, INZ-701, is an ENPP1 Fc fusion protein enzyme replacement therapy designed to restore pyrophosphate and adenosine levels. INZ-701 is currently in late-stage clinical development in ENPP1 Deficiency, with the potential to expand into additional indications where deficiencies in the Pyrophosphate-Adenosine Pathway contribute to disease pathology, including ABCC6 Deficiency and calciphylaxis.

我们的主要研究性疗法 INZ-701 是一种 ENPP1 Fc 融合蛋白酶替代疗法，旨在恢复焦磷酸盐和腺苷水平。INZ-701 目前正处于 ENPP1 缺乏症的后期临床开发阶段，并有潜力扩展到其他适应症，其中焦磷酸盐-腺苷通路的缺陷会导致疾病病理，包括 ABCC6 缺乏症和钙化防御。

Through our pioneering work, we aim to transform treatment options for patients affected by these devastating conditions..

通过我们的开创性工作，我们旨在改变受这些毁灭性疾病影响患者的治疗选择。

Forward-Looking Statements

前瞻性声明

This press release contains forward-looking statements about, among other things, the acquisition of Inozyme Pharma, Inc. ('Inozyme') by BioMarin Pharmaceutical Inc. ('BioMarin') and the business prospects of Inozyme and BioMarin, including, without limitation, statements about: the prospective benefits of the acquisition; Inozyme's product candidate INZ-701 and expectations regarding its ongoing development, including the potential for INZ-701 to be the first treatment for people living with ENPP1 Deficiency; and other statements that are not historical facts.

本新闻稿包含关于BioMarin制药公司（“BioMarin”）收购Inozyme制药公司（“Inozyme”）及其他事项的前瞻性声明，涉及Inozyme和BioMarin的业务前景，包括但不限于：收购的潜在益处；Inozyme的产品候选药物INZ-701及其持续开发的预期，包括INZ-701可能成为治疗ENPP1缺乏症患者的首个疗法的潜力；以及其他非历史事实的声明。

Actual results could differ materially from those anticipated in these forward-looking statements. Except as required by law, each of BioMarin and Inozyme assume no obligation to update these forward-looking statements, whether as a result of new information, future events or otherwise. These statements, which represent each of BioMarin's and Inozyme's current expectations or beliefs concerning various future events that are subject to significant risks and uncertainties, may contain words such as 'may,' 'will,' 'would,' 'could,' 'expect,' 'anticipate,' 'intend,' 'plan,' 'believe,' 'estimate,' 'project,' 'seek,' 'should,' 'strategy,' 'future,' 'opportunity,' 'potential' or other similar words and expressions indicating future results. .

实际结果可能与这些前瞻性陈述中预期的结果有重大差异。除非法律要求，BioMarin和Inozyme均不承担更新这些前瞻性陈述的义务，无论是否由于新信息、未来事件或其他原因。这些陈述代表了BioMarin和Inozyme当前对未来事件的预期或信念，涉及重大风险和不确定性，可能包含诸如“可能”、“将”、“会”、“能够”、“预计”、“预期”、“打算”、“计划”、“相信”、“估计”、“预测”、“寻求”、“应该”、“策略”、“未来”、“机会”、“潜力”等词语或其他类似的表达未来结果的词汇。

These forward-looking statements are predictions and involve risks and uncertainties such that actual results may differ materially from these statements. Forward-looking statements reflect current beliefs and expectations; however, these statements involve inherent risks and uncertainties, including, without limitation, with respect to: the effects of the acquisition on BioMarin's stock price and operating results; unknown or inestimable liabilities; the development, launch and commercialization of products and product candidates such as INZ-701, if approved; the successful completion of regulatory activities with respect to INZ-701; the parties' ability to realize the anticipated benefits of the acquisition, including the possibility that the expected benefits from the acquisition will not be realized or will not be realized within the expected time period and that BioMarin and Inozyme will not be integrated successfully or that such integration may be more difficult, time-consuming or costly than expected; obtaining and maintaining adequate coverage and reimbursement for BioMarin's or Inozyme's products; the costly and time-consuming pharmaceutical product development process and the uncertainty of clinical success, including risks related to failure or delays in successfully initiating or completing clinical trials and assessing patients, including with respect to current and planned future clinical trials of INZ-701; global economic, financial, and healthcare system disruptions and the current and potential future negative impacts to BioMarin's or Inozyme's business operations and financial results; the sufficiency of BioMarin's or Inozyme's cash flows and capital resources; BioMarin's evaluation of the accounting treatment of the acquisition and its potential impa.

这些前瞻性陈述是预测性的，涉及风险和不确定性，可能导致实际结果与这些陈述存在重大差异。前瞻性陈述反映了当前的信念和期望；然而，这些陈述涉及固有的风险和不确定性，包括但不限于：收购对BioMarin股价和经营结果的影响；未知或无法估量的负债；诸如INZ-701等产品及其候选产品的开发、上市和商业化（如果获批）；关于INZ-701的成功监管活动完成情况；各方实现收购预期效益的能力，包括可能无法实现预期效益或无法在预期时间内实现，以及BioMarin和Inozyme可能无法成功整合或整合可能比预期更困难、耗时或成本更高的风险；为BioMarin或Inozyme的产品获取并维持足够的覆盖范围和报销；昂贵且耗时的医药产品开发过程及临床成功的不确定性，包括与未能或延迟成功启动或完成临床试验和评估患者相关的风险，尤其是关于INZ-701当前和未来计划中的临床试验；全球经济、金融和医疗系统中断以及当前和潜在未来对BioMarin或Inozyme业务运营和财务结果的负面影响；BioMarin或Inozyme现金流和资本资源的充足性；BioMarin对收购会计处理的评估及其潜在影响。

March 31, 2025

2025年3月31日

and Inozyme's Quarterly Report on Form 10-Q for the fiscal quarter ended

以及Inozyme截至本财季的10-Q季度报告

March 31, 2025

2025年3月31日

, as such risk factors may be updated by any subsequent reports, as well as the Tender Offer Statement on Schedule TO and related tender offer documents, as amended, filed by BioMarin and its acquisition subsidiary, Incline Merger Sub, Inc., and the Solicitation/Recommendation Statement on Schedule 14D-9, as amended, filed by Inozyme.

，因为此类风险因素可能会被任何后续报告更新，还包括BioMarin及其收购子公司Incline Merger Sub, Inc.提交的附表TO中的要约收购声明及相关要约收购文件（经修订），以及Inozyme提交的附表14D-9中的征求/建议声明（经修订）。

Stockholders of BioMarin and Inozyme are urged not to place undue reliance on forward-looking statements, which speak only as of the date hereof. BioMarin and Inozyme are under no obligation, and expressly disclaim any obligation, to update (publicly or otherwise) or alter any forward-looking statement, including without limitation any financial projection or guidance, whether as a result of new information, future events or otherwise..

BioMarin 和 Inozyme 的股东被敦促不要过分依赖前瞻性声明，这些声明仅截至本日期有效。BioMarin 和 Inozyme 没有义务，并明确否认任何更新（公开或其他方式）或更改任何前瞻性声明的义务，包括但不限于任何财务预测或指导，无论是否由于新信息、未来事件或其他原因。

BioMarin

生物马林

is a registered trademark of BioMarin Pharmaceutical Inc. or its affiliates. Inozyme

是BioMarin制药公司或其附属公司的注册商标。Inozyme

is a registered trademark of Inozyme Pharma Inc. or its affiliates.

是Inozyme制药公司或其附属公司的注册商标。

Contacts:

联系人：

Investors

投资者

Media